CRISPR Therapeutics AG (CRSP) Has Great Growth Outlook For 2022
CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 1.93 and has seen 1.58 million shares traded in the last trading session. The company, currently
CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 1.93 and has seen 1.58 million shares traded in the last trading session. The company, currently
In today’s recent session, 0.68 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) have been traded, and its beta is 1.94. Most recently the company’s
CRISPR Therapeutics AG (NASDAQ: CRSP) expects to submit an application for gene therapy approval by the end of the year. This medicine already earned good
CRISPR Therapeutics AG (NASDAQ:CRSP)’s traded shares stood at 1.2 million during the last session, with the company’s beta value hitting 1.96. At the close of
In the last trading session, 1.19 million CRISPR Therapeutics AG (NASDAQ:CRSP) shares changed hands as the company’s beta touched 1.96. With the company’s per share
In last trading session, CRISPR Therapeutics AG (NASDAQ:CRSP) saw 2.2 million shares changing hands with its beta currently measuring 1.89. Company’s recent per share price
CRISPR Therapeutics AG (NASDAQ:CRSP) has a beta value of 1.89 and has seen 1.54 million shares traded in the last trading session. The company, currently
During the last session, CRISPR Therapeutics AG (NASDAQ:CRSP)’s traded shares were 3.25 million, with the beta value of the company hitting 1.93. At the end
In the last trading session, 1.73 million shares of the CRISPR Therapeutics AG (NASDAQ:CRSP) were traded, and its beta was 1.93. Most recently the company’s